Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update

GlobeNewswire August 10, 2016

Affimed Announces Second Quarter 2016 Financial Results and Corporate Update Conference Call

GlobeNewswire August 3, 2016

Affimed to Present at the Jefferies 2016 Healthcare Conference

GlobeNewswire May 31, 2016

Affimed Announces Annual General Meeting of Shareholders

GlobeNewswire May 23, 2016

Affimed Reports Financial Results for First Quarter 2016

GlobeNewswire May 18, 2016

Affimed to Present at the UBS Global Healthcare Conference -- New York

GlobeNewswire May 17, 2016

Affimed Announces First Quarter 2016 Financial Results and Corporate Update Conference Call

GlobeNewswire May 11, 2016

Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016

GlobeNewswire April 21, 2016

Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016

GlobeNewswire April 21, 2016

Affimed Reports Financial Results for Fourth Quarter and Year End 2015

GlobeNewswire March 30, 2016

Affimed Announces Fourth Quarter and Year End 2015 Financial Results and Corporate Update Conference Call

GlobeNewswire March 23, 2016

Affimed to Present Data on NK- and T-Cell Engagers at the AACR Annual Meeting 2016

GlobeNewswire March 17, 2016

Affimed to Present at the Cowen and Company 36th Annual Health Care Conference

GlobeNewswire February 29, 2016

Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

GlobeNewswire February 22, 2016

Affimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference

GlobeNewswire February 4, 2016

Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA(R) (pembrolizumab) for Patients with Hodgkin Lymphoma

GlobeNewswire January 25, 2016

Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board

GlobeNewswire January 21, 2016

Affimed to Host Hodgkin's Lymphoma Day with Key Opinion Leaders on January 26th in New York City

GlobeNewswire January 20, 2016

Affimed Announces Addition of Dr. Andrew Evens to Scientific Advisory Board

GlobeNewswire January 14, 2016

Affimed to Present at Noble Financial Capital Markets' 12th Annual Investor Conference

GlobeNewswire January 12, 2016